Crinetics Pharmaceuticals (CRNX) News Today $37.35 +0.87 (+2.38%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Crinetics Pharmaceuticals, Inc. (CRNX): The Biotech Stock with Biggest Upside PotentialJanuary 17 at 11:37 AM | insidermonkey.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 5.2% - Here's WhyCrinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 5.2% - Should You Sell?January 16 at 9:16 PM | marketbeat.comPiper Sandler Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)January 16 at 8:50 PM | markets.businessinsider.comCrinetics Pharmaceuticals' (CRNX) "Buy" Rating Reiterated at HC WainwrightJanuary 14, 2025 | americanbankingnews.comPromising Phase 2 Results for Atumelnant Boost Crinetics Pharmaceuticals’ Buy RatingJanuary 13, 2025 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)January 13, 2025 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for Crinetics Pharmaceuticals (NASDAQ:CRNX)HC Wainwright reiterated a "buy" rating and set a $81.00 target price on shares of Crinetics Pharmaceuticals in a research report on Monday.January 13, 2025 | marketbeat.comStrong Buy Recommendation for Crinetics Pharmaceuticals Driven by Promising Atumelnant Phase 2 Trial ResultsJanuary 12, 2025 | markets.businessinsider.comCrinetics Pharmaceuticals: Promising Phase 2 Results and Strong Growth Potential Lead to Buy RatingJanuary 11, 2025 | markets.businessinsider.comCrinetics Pharmaceuticals: Promising Trial Data and Strategic Advancements Support Buy RatingJanuary 11, 2025 | markets.businessinsider.comCrinetics Pharmaceuticals’ Atumelnant Trial Data Prompts Hold Rating Amid Efficacy and Safety ConcernsJanuary 10, 2025 | markets.businessinsider.comCrinetics Pharmaceuticals Receives Buy Rating on Promising Phase 2 Trial Results and Strong Financial PositionJanuary 10, 2025 | markets.businessinsider.comCrinetics Pharmaceuticals Advances Atumelnant After Successful Phase 2January 10, 2025 | markets.businessinsider.comStrong Buy Rating for Crinetics Pharmaceuticals Driven by Promising Atumelnant Data and Market PotentialJanuary 10, 2025 | markets.businessinsider.comCrinetics falls after mid-stage trial data adrenal disorder therapyJanuary 10, 2025 | msn.comCrinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 10, 2025 | globenewswire.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Sees Large Volume Increase - Here's What HappenedCrinetics Pharmaceuticals (NASDAQ:CRNX) Sees Unusually-High Trading Volume - Still a Buy?January 10, 2025 | marketbeat.comCrinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)January 10, 2025 | globenewswire.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Trading Down 3.5% - What's Next?Crinetics Pharmaceuticals (NASDAQ:CRNX) Trading Down 3.5% - What's Next?January 6, 2025 | marketbeat.comCrinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | globenewswire.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Principal Financial Group Inc.Principal Financial Group Inc. lifted its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 488.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 77,709 shares of the company's stock after acquiring an additional 64,504 shJanuary 3, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Recommendation of "Buy" by BrokeragesCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) has been given an average rating of "Buy" by the ten brokerages that are presently covering the company, MarketBeat.com reports. Ten research analysts have rated the stock with a buy rating. The average twelve-month price target amongJanuary 3, 2025 | marketbeat.comCrinetics Pharmaceuticals: Attractive Speculative Bet On Market WeaknessJanuary 2, 2025 | seekingalpha.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Geode Capital Management LLCGeode Capital Management LLC increased its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 10.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,848,133 shares of the company's stock after acquiring an additional 169,746 shDecember 20, 2024 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Stock Quotes, Forecast and News SummaryDecember 18, 2024 | benzinga.comCrinetics Pharmaceuticals Strengthens Leadership with New AppointmentDecember 17, 2024 | markets.businessinsider.comFranklin Resources Inc. Increases Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Franklin Resources Inc. increased its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 61.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,390,110 shares of the company's stoDecember 17, 2024 | marketbeat.comBarclays PLC Purchases 89,358 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Barclays PLC raised its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 75.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 207,712 shares of the company'December 17, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Short Interest UpdateCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) was the recipient of a significant decline in short interest in November. As of November 30th, there was short interest totalling 6,010,000 shares, a decline of 7.5% from the November 15th total of 6,500,000 shares. Based on an average daily trading volume, of 713,200 shares, the short-interest ratio is presently 8.4 days.December 16, 2024 | marketbeat.comCrinetics Pharmaceuticals' (CRNX) Market Outperform Rating Reiterated at JMP SecuritiesJMP Securities restated a "market outperform" rating and issued a $87.00 price objective on shares of Crinetics Pharmaceuticals in a research report on Monday.December 16, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Addus Homecare (ADUS)December 16, 2024 | markets.businessinsider.comLord Abbett & CO. LLC Has $38.13 Million Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Lord Abbett & CO. LLC lowered its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 16.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 746,118 shares of the company's stock after selling 141,8December 15, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by State Street CorpState Street Corp grew its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 0.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,838,484 shares ofDecember 14, 2024 | marketbeat.comBNP Paribas Financial Markets Boosts Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)BNP Paribas Financial Markets increased its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 134.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,942 shaDecember 11, 2024 | marketbeat.comCrinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 10, 2024 | globenewswire.comCrinetics announces FDA acceptance of NDA for paltusotineDecember 10, 2024 | markets.businessinsider.comPromising Prospects for Crinetics Pharmaceuticals: Buy Rating Driven by Potential Paltusotine Approval and Expansive PipelineDecember 9, 2024 | markets.businessinsider.comCrinetics Pharmaceuticals: FDA To Review NDA For Paltusotine - Quick FactsDecember 9, 2024 | markets.businessinsider.comCrinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with AcromegalyDecember 9, 2024 | globenewswire.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Position Trimmed by Wellington Management Group LLPWellington Management Group LLP lowered its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 3.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,459,691 shares of the company's stock after selling 160,722December 9, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and ten have issuDecember 9, 2024 | marketbeat.comCastleark Management LLC Takes $3.75 Million Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Castleark Management LLC bought a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 73,340 shares of the company's stock, valued at approximately $3,748,000. CastlearDecember 8, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 4.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor oDecember 8, 2024 | marketbeat.comCrinetics price target raised to $87 from $80 at JMP SecuritiesDecember 5, 2024 | markets.businessinsider.comJanus Henderson Group PLC Reduces Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Janus Henderson Group PLC lowered its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 1.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,429,450December 5, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC lowered its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 45.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 77December 4, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock Holdings Raised by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. lifted its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 9.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 655,418 shares of the company's stock after purchasing an addDecember 4, 2024 | marketbeat.comCinctive Capital Management LP Invests $2.53 Million in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Cinctive Capital Management LP bought a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 49,445 shares of the company's stock, valued at approximatelyDecember 3, 2024 | marketbeat.comFmr LLC Purchases 358,975 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Fmr LLC raised its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 8.8% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 4,455,770 shares of the company's stock after acquiring an additional 358,975 shares duringDecember 3, 2024 | marketbeat.comMartingale Asset Management L P Makes New $1.13 Million Investment in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Martingale Asset Management L P bought a new position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 22,074 sharDecember 2, 2024 | marketbeat.com Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address CRNX Media Mentions By Week CRNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRNX News Sentiment▼0.500.64▲Average Medical News Sentiment CRNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRNX Articles This Week▼127▲CRNX Articles Average Week Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Viatris News Today Intra-Cellular Therapies News Today Summit Therapeutics News Today Moderna News Today Dr. Reddy's Laboratories News Today Catalent News Today Sarepta Therapeutics News Today Qiagen News Today Vaxcyte News Today Ascendis Pharma A/S News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRNX) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
